KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Sarepta Therapeutics (SRPT) over the last 14 years, with Q3 2025 value amounting to $36.3 million.

  • Sarepta Therapeutics' Other Non-Current Liabilities fell 2341.77% to $36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.3 million, marking a year-over-year decrease of 2341.77%. This contributed to the annual value of $47.4 million for FY2024, which is 2440.94% up from last year.
  • Sarepta Therapeutics' Other Non-Current Liabilities amounted to $36.3 million in Q3 2025, which was down 2341.77% from $47.4 million recorded in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' Other Non-Current Liabilities peaked at $50.8 million during Q1 2021, and registered a low of $36.1 million during Q2 2023.
  • Its 5-year average for Other Non-Current Liabilities is $43.2 million, with a median of $43.6 million in 2021.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 39570.65% in 2021, then crashed by 2341.77% in 2025.
  • Sarepta Therapeutics' Other Non-Current Liabilities (Quarter) stood at $43.6 million in 2021, then dropped by 15.37% to $36.9 million in 2022, then grew by 3.25% to $38.1 million in 2023, then increased by 24.41% to $47.4 million in 2024, then fell by 23.42% to $36.3 million in 2025.
  • Its Other Non-Current Liabilities was $36.3 million in Q3 2025, compared to $47.4 million in Q2 2025 and $47.4 million in Q1 2025.